Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial

Peking University

Status and phase: Begins enrollment in 1 month; Phase 4

Conditions: Platelet Rich Plasma; Allogeneic Blood Transfusions; Diabetic Wounds; Renal Dysfunction

Treatments: Drug: autologous platelet plasma; Drug: allogeneic platelet plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT07020559

Long2025-DW-alPRP

Details and patient eligibility

About

Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect. Comparing the efficacy and safety differences between allogeneic platelet plasma and autologous platelet plasma is of significant importance and value for the clinical application.

Full description

This study is a single-center, randomized, parallel control, superior trial. Fifty-six renal dysfunction patients with diabetic-related wound after wound bed preparation will be randomly assigned to the autologous platelet plasma group and allogeneic platelet plasma group in a 1:1 ratio. The primary outcome is the wound healing rate at 4 weeks (Stitches removal). The secondary outcomes include the wound healing rates at 3 weeks, the reduction rate of wound area at 2-, 3- and 4- weeks, healing time, post-operative wound infection, 7-day, 2-, 3-, 4-week pain relief progression assessed by Visual Analog Scale, incidence of mortality, reoperation, and adverse events during the follow-up period.

Enrollment: 56 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The patient is aged 18-80 years old;

2. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;

3. Abnormal renal function defined as:

   • Serum creatinine >106 μmol/L (men) or >97 μmol/L (women)
   • AND eGFR <90 mL/min/1.73m² (CKD-EPI) ；

4. The patient has diabetes wounds with poor healing or prolonged healing need standard wound treatment;

5. After preparing the wound bed, the condition for using platelet plasma to close the wound is met*;

6. Voluntarily sign an informed consent form;

Exclusion criteria

1. Blood glucose is out of control or not yet effectively controlled，;
2. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;
3. Active bleeding inside the wound, and routine basic treatment plans cannot be implemented；
4. Uncontrolled systemic or disseminated infections;
5. Patients with advanced malignant tumors;
6. Pregnant or lactating women；
7. The patient is unable to cooperate or has mental disorders;
8. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

56 participants in 2 patient groups

autologous platelet plasma group

Active Comparator group

Description:

diabetic-related wounds after wound bed preparation are treated by the autologous platelet plasma

Treatment:

Drug: autologous platelet plasma

allogeneic platelet plasma group

Experimental group

Description:

diabetic-related wounds after wound bed preparation are treated by the allogeneic platelet plasma

Treatment:

Drug: allogeneic platelet plasma